| 3.5 0.4 (12.9%) | 06-18 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 5.6 | 1-year : | 6.87 |
| Resists | First : | 4.79 | Second : | 5.88 |
| Pivot price | 3.99  |
|||
| Supports | First : | 3.03 | Second : | 2.52 |
| MAs | MA(5) : | 3.33 |
MA(20) : | 4.27 |
| MA(100) : | 5.76 |
MA(250) : | 9.12 |
|
| MACD | MACD : | -0.6 |
Signal : | -0.5 |
| %K %D | K(14,3) : | 8 |
D(3) : | 3.6 |
| RSI | RSI(14): 35.2 |
|||
| 52-week | High : | 14.64 | Low : | 3.03 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ CVKD ] has closed above bottom band by 27.2%. Bollinger Bands are 13.4% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 3.61 - 3.62 | 3.62 - 3.64 |
| Low: | 3.15 - 3.17 | 3.17 - 3.19 |
| Close: | 3.47 - 3.5 | 3.5 - 3.53 |
Cadrenal Therapeutics, Inc. operates as a biopharmaceutical enterprise primarily engaged in clinical development. The company's core focus is the advancement of Tecarfarin, a novel therapeutic agent that has received orphan drug designation. This treatment is engineered to prevent systemic thromboembolism originating from cardiac issues in patients suffering from both end-stage renal disease and atrial fibrillation. Established in 2022, the firm is headquartered in Ponte Vedra, Florida.
Thu, 18 Jun 2026
Cadrenal CEO Pham sells $13,110 in company stock By Investing.com - Investing.com India
Thu, 18 Jun 2026
Cadrenal (CVKD) CEO Pham sells 4,126 shares, retains large stake via trust - Stock Titan
Mon, 15 Jun 2026
Cadrenal Therapeutics chairman, CEO Pham sells $70,351 in shares - Investing.com UK
Mon, 15 Jun 2026
Cadrenal (CVKD) CEO sells shares under Rule 10b5-1 trading plan - Stock Titan
Mon, 15 Jun 2026
CVKD (NASDAQ: CVKD) Form 144 lists Quang X. Pham sales of common stock - Stock Titan
Mon, 15 Jun 2026
New trial targets kidney injury after heart surgery in $1B market - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 3 (M) |
| Shares Float | 2 (M) |
| Held by Insiders | 17.4 (%) |
| Held by Institutions | 5.9 (%) |
| Shares Short | 69 (K) |
| Shares Short P.Month | 54 (K) |
| EPS | -5.6 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.72 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -139.3 % |
| Return on Equity (ttm) | -300.6 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -3.92 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -11 (M) |
| Levered Free Cash Flow | -6 (M) |
| PE Ratio | -0.63 |
| PEG Ratio | 0 |
| Price to Book value | 4.86 |
| Price to Sales | 0 |
| Price to Cash Flow | -0.99 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|